デフォルト表紙
市場調査レポート
商品コード
1492530

デービック症候群治療市場:治療、流通チャネル、エンドユーザー別-2024年~2030年の世界予測

Devic's Syndrome Treatment Market by Treatment (Corticosteroids, Immunosuppressants, Plasma Exchange (Plasmapheresis)), Distribution Channel (Clinics, Hospitals, Online Pharmacies), End User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 191 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
デービック症候群治療市場:治療、流通チャネル、エンドユーザー別-2024年~2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 191 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

デービック症候群治療市場規模は2023年に2億1,053万米ドルと推定され、2024年には2億2,027万米ドルに達し、CAGR 4.68%で2030年には2億9,003万米ドルに達すると予測されます。

視神経脊髄炎(NMO)としても知られるデービック症候群は、中枢神経系(CNS)の慢性疾患で、主に患者の視神経と脊髄に影響を及ぼします。この疾患は、免疫系が健康な細胞を攻撃することで発症し、さまざまな程度の失明や麻痺を引き起こすことがあります。治療戦略は通常、症状を管理し、再発を予防することを目的としています。教育やアドボカシー・キャンペーンを通じてデービック症候群に対する認識が世界的に高まっていることは、早期診断・早期治療に役立っています。ヘルスケアのインフラやアクセスの改善により、より多くの患者がタイムリーで適切な治療を受けられるようになり、デービック症候群の治療法の普及が進んでいます。しかし、副作用の可能性や、既存の治療法ではデビック症候群を効果的に治療・管理できないことが、ヘルスケアソリューションに対する患者の信頼を低下させる可能性があります。さらに、デビック症候群の希少性は、研究資金や医薬品開発を複雑にしており、この領域は、より一般的な疾患と比較して、あまり研究されていないことが多いです。遺伝子治療を探求することは、将来、デービック症候群を治療し、あるいは治癒させる新しい方法を提供する可能性があります。遺伝子プロファイルに基づいた個別化治療計画の作成は、治療成績を改善する可能性があります。

主な市場の統計
基準年[2023] 2億1,053万米ドル
予測年[2024] 2億2,027万米ドル
予測年 [2030] 2億9,003万米ドル
CAGR(%) 4.68%

地域別インサイト

南北アメリカ地域、特に米国とカナダでは、最近の標的治療薬の承認により、デービック症候群の治療選択肢は大きく発展しています。また、強固なヘルスケアインフラと複数の疾患に対する保険適用により、患者がデビック症候群の治療にアクセスしやすい環境が整っています。患者支援団体は、保険適用のためのロビー活動や新しい治療法の研究資金を得るために重要な役割を果たしています。研究への投資は活発で、国立衛生研究所などの政府機関や民間企業によって支えられています。欧州連合(EU)諸国は、EU規制の下、デビック症候群を含む希少疾病分野の研究開発を支援するというコミットメントを共有しています。新しい治療法に対する欧州医薬品庁(EMA)の承認は、欧州全域における消費者のアクセスを定義する上で極めて重要です。患者アクセス制度や政府からの資金援助は、治療費が高額になりがちな消費者の購買行動に大きな影響を与えます。APACではヘルスケア制度が急速に拡大し、政府および民間部門によるヘルスケアへの投資が増加しており、希少疾患にも焦点が当てられています。APACにおける最近の特許動向は、デービック症候群のような疾患に対する新規治療法の開発への関心が高まっていることを示唆しており、バイオテクノロジーのイノベーションを後押しすることを目的とした国家資金によるプログラムやイニシアチブがこれを後押ししています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、デービック症候群治療市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、ビジネス戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、デービック症候群治療市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象期間の累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、デービック症候群治療市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中でデビック症候群の発生が増加
      • 神経疾患に対する意識を高める取り組みと支援団体の出現
      • デビック症候群の治療へのアクセスを確保するための好ましい規制承認と政府の取り組み
    • 抑制要因
      • 病気の複雑さとデビック症候群に対処する治療法の無力さ
    • 機会
      • デービック症候群治療ソリューションの有効性と安全性を向上させるための継続的な取り組み
      • 患者は個別化された特定の治療戦略を好む
    • 課題
      • デビック症候群の治療薬の副作用の可能性
  • 市場セグメンテーション分析
    • 治療:デビック症候群では、炎症を速やかに抑える効果があるため、コルチコステロイドを使用します。
    • エンドユーザー:成人患者向けの包括的なデービック症候群治療計画の開発
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 デービック症候群治療市場:治療別

  • コルチコステロイド
  • 免疫抑制剤
  • 血漿交換(血漿交換)

第7章 デービック症候群治療市場:流通チャネル別

  • クリニック
  • 病院
  • オンライン薬局

第8章 デービック症候群治療市場:エンドユーザー別

  • 成人患者
  • 小児患者

第9章 南北アメリカのデービック症候群治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋のデービック症候群治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのデービック症候群治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析、2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
    • FDAが視神経脊髄炎スペクトラム障害の治療薬としてウルトミリスを承認、治療範囲を拡大
    • カナダ保健省、NMOSDの成人患者にUPLIZNAを承認
    • 中外製薬のNMOSD患者向けエンスプリングが台湾で発売
  • 戦略分析と提言

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DEVIC'S SYNDROME TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 283. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-CB04E05660A7

[191 Pages Report] The Devic's Syndrome Treatment Market size was estimated at USD 210.53 million in 2023 and expected to reach USD 220.27 million in 2024, at a CAGR 4.68% to reach USD 290.03 million by 2030.

Devic's Syndrome, also known as neuromyelitis optica (NMO), is a chronic disorder of the central nervous system(CNS) that primarily affects the patient's optic nerves and spinal cord. The condition involves the immune system attacking healthy cells and can result in varying degrees of blindness and paralysis. Treatment strategies typically aim to manage symptoms and prevent relapses. Rising awareness of Devic's Syndrome globally through education and advocacy campaigns helps in early diagnosis and treatment. Improvements in healthcare infrastructure and accessibility allow more patients to receive timely and appropriate treatment, thereby increasing the adoption of treatments for Devic's Syndrome. However, the possibility of side effects and the inability of existing treatments to effectively target and manage Devic's Syndrome can reduce patient trust in the healthcare solution. Moreover, the rarity of Devic's Syndrome complicates research funding and drug development, often leaving this area less explored than more prevalent diseases. Exploring gene therapy could offer new ways to treat or possibly cure Devic's Syndrome in the future. Creating personalized treatment plans based on genetic profiles could improve treatment outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 210.53 million
Estimated Year [2024] USD 220.27 million
Forecast Year [2030] USD 290.03 million
CAGR (%) 4.68%

Regional Insights

In the Americas region, particularly in the United States and Canada, treatment options for Devic's Syndrome have evolved significantly with recent approvals of targeted therapies. A robust healthcare infrastructure and significant insurance coverage of several diseases have also created a favorable landscape for patients to access treatment for Devic's Syndrome. Patient advocacy groups play a crucial role in lobbying for insurance coverage and funding for research into new treatments. Investment in research is robust and supported by government bodies such as the National Institutes of Health and private enterprises. European Union countries share a commitment under EU regulations to support research and development in the field of rare diseases, including Devic's Syndrome. European Medicines Agency(EMA) approvals for new treatments are critical in defining consumer access across Europe. Patient access schemes and governmental funding significantly impact consumer purchasing behaviors, as treatments can be expensive. APAC's rapidly expanding healthcare system and increased investment in healthcare from both government and private sectors include a focus on rare diseases. Recent patents in APAC suggest a growing interest in developing novel treatments for conditions such as Devic's Syndrome, supported by state-funded programs and initiatives aimed at boosting biotechnology innovations.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Devic's Syndrome Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing incidences of Devic's Syndrome across the world
      • Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
      • Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
    • Market Restraints
      • Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
    • Market Opportunities
      • Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
      • Patient preference for personalized and specific treatment strategies
    • Market Challenges
      • Possibility of side effects of the treatment solutions for Devic's Syndrome
  • Market Segmentation Analysis
    • Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
    • End User: Development of a comprehensive Devic's Syndrome treatment plans for adult patients
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Devic's Syndrome Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Devic's Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope

The FDA has approved Ultomiris (ravulizumab-cwvz) for treating adult patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies. This decision was supported by data from the phase 3 CHAMPION-NMOSD trial. Ultomiris, a long-acting C5 complement inhibitor, is also used to treat other serious conditions such as generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome, highlighting its versatility in managing autoimmune and hematologic disorders. [Published On: 2024-03-25]

Health Canada Approves UPLIZNA for Adults with NMOSD

Horizon Therapeutics, a subsidiary of Amgen, announced that UPLIZNA (inebilizumab for injection) received approval from Health Canada. This approval allows it to be used as a single-agent treatment for adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who test positive for AQP4-IgG, a critical identifier in this rare, debilitating autoimmune condition. NMOSD primarily causes severe inflammation within the central nervous system, leading to recurrent, serious attacks that can result in permanent disabilities such as vision loss and paralysis. [Published On: 2024-01-16]

Chugai Pharmaceutical's Enspryng Launches in Taiwan for NMOSD Patients

Chugai Pharma Taiwan Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd., introduced Enspryng in Taiwan. This drug is tailored for adults and adolescents aged 12 and above who test positive for the anti-aquaporin-4 (AQP4) antibody, targeting neuromyelitis optica spectrum disorder (NMOSD). Earlier, the Ministry of Health and Welfare recognized Enspryng as an orphan drug, followed by its approval from the Taiwan Food and Drug Administration. This introduction marks Enspryng as a dedicated treatment for this patient group in Taiwan, showcasing a significant advancement in NMOSD care within the region. [Published On: 2023-10-02]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Devic's Syndrome Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Devic's Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., Alexion Pharmaceuticals, Inc by AstraZeneca PLC, Anant Pharmaceuticals Pvt. Ltd., Apple Pharmaceuticals, Cadila Pharmaceuticals Limited, Chugai Pharma Taiwan Ltd., Conscientia Industrial Co., Ltd, Evidentic GmbH, F. Hoffmann-La Roche Ltd, Healthy Life Pharma Pvt. Ltd., Horizon Therapeutics plc by Amgen, Inc., LEXICARE PHARMA PVT. LTD., Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics, Inc., Samsung Bioepis Co., Ltd. by Samsung Biologics, Teva Pharmaceutical Industries Ltd., TG Therapeutics, Inc., Thermo Fisher Scientific Inc., and West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC.

Market Segmentation & Coverage

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Corticosteroids
    • Immunosuppressants
    • Plasma Exchange (Plasmapheresis)
  • Distribution Channel
    • Clinics
    • Hospitals
    • Online Pharmacies
  • End User
    • Adult Patients
    • Pediatric Patients
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of Devic's Syndrome across the world
      • 5.1.1.2. Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
      • 5.1.1.3. Favorable regulatory approvals and government initiatives to ensure access to Devic's syndrome treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of the disease and the inability of treatments to tackle Devic's Syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing initiatives to improve the efficacy and safety of Devic's Syndrome treatment solutions
      • 5.1.3.2. Patient preference for personalized and specific treatment strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Possibility of side effects of the treatment solutions for Devic's Syndrome
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
    • 5.2.2. End User: Development of a comprehensive Devic's Syndrome treatment plans for adult patients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Devic's Syndrome Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Immunosuppressants
  • 6.4. Plasma Exchange (Plasmapheresis)

7. Devic's Syndrome Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals
  • 7.4. Online Pharmacies

8. Devic's Syndrome Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Adult Patients
  • 8.3. Pediatric Patients

9. Americas Devic's Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Devic's Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Devic's Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope
    • 12.3.2. Health Canada Approves UPLIZNA for Adults with NMOSD
    • 12.3.3. Chugai Pharmaceutical's Enspryng Launches in Taiwan for NMOSD Patients
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio